ArticleVeterinary research communications2025
Therapeutic effects of adipose mesenchymal stem cell-derived exosomes on limbal stem cells deficiency in cats.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mesenchymal Stem Cell-Derived Exosomes in Skin Wound Healing and Scar Prevention: Mechanisms, Comparison, and Clinical Prospects.Tissue engineering and regenerative medicine · 2026Review
- The Therapeutic Potential of Exosomes in Ocular Surface Diseases.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Corneal transparency is maintained by the limbus and its stem cells, and damage or deficiency in this region leads to conjunctivalization and subsequent vision impairment. This study aims to evaluate the therapeutic effects of feline adipose mesenchymal stem cell-derived exosomes (fAD-MSCExo) in the treatment of limbal stem cell deficiency in cats. For this purpose, 30 animals presenting with severe conjunctivalization were included in the study. Cats were randomly assigned to two groups: Group 1 (n = 15), serving as the control group and receiving steroid treatment, Group 2 (n = 15), receiving fAD-MSCExo therapy. Exosomes were produced from fAD-MSCs isolated from intra-abdominal adipose tissue obtained from three healthy donor cats. Detailed ophthalmologic examination and impression cytology were performed on all animals preoperatively and on postoperative days 0, 10, and 30. Periodic acid-schiff staining was used to detect goblet cells, while Immunofluorescence staining was performed to identify K13 cytokeratin antibodies. At postoperative day 10, no significant clinical or histological differences were observed between the two groups. However, after treatment discontinuation, by postoperative day 30, clinical improvement had regressed in the steroid-treated group, whereas corneal epithelial regeneration and, consequently, limbal repair had progressed satisfactorily in the exosome-treated group. This study demonstrated that even short-term use of exosomes is effective in the treatment of limbal stem cell deficiency in cats. The presented data suggest that fAD-MSCExo may offer a potential definitive solution for the management of this widespread pathology, which requires long-term follow-up, thereby generating significant interest in further research in this field.
Indexed as
Identifiers
41055800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.